Cholestatic Liver Disease Therapeutics
1. Livmarli patent expiration
Treatment: Treatment of cholestatic pruritus in patients with alagille syndrome (algs); Treatment of cholestatic pruritus in patients 12 months of age and older with progressive familial intrahepatic cholestasis...
Can you believe LIVMARLI received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11497745 | MIRUM | Methods for treating cholestasis |
Feb, 2040
(14 years from now) | |
| US11260053 | MIRUM | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
May, 2031
(5 years from now) | |
| US11229661 | MIRUM | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
Oct, 2032
(6 years from now) | |
| US11229647 | MIRUM | Methods for treating cholestasis |
Feb, 2040
(14 years from now) | |
| US10512657 | MIRUM | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
Oct, 2032
(6 years from now) | |
| US11376251 | MIRUM | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
Oct, 2032
(6 years from now) | |
| US12350267 | MIRUM | NA |
Oct, 2032
(6 years from now) | |
| US12296050 | MIRUM | Pharmaceutical compositions comprising maralixibat and uses thereof |
Oct, 2043
(17 years from now) | |
| US11918578 | MIRUM | Methods for treating cholestasis |
Feb, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Mar 13, 2026 |
| New Chemical Entity Exclusivity(NCE) | Sep 29, 2026 |
| New Indication(I-938) | Mar 13, 2027 |
| Orphan Drug Exclusivity(ODE-379) | Sep 29, 2028 |
| Orphan Drug Exclusivity(ODE-429) | Mar 13, 2030 |
| ODE*(ODE*) | Mar 13, 2031 |
| Orphan Drug Exclusivity(ODE-471) | Mar 13, 2031 |
| Orphan Drug Exclusivity(ODE-490) | Jul 24, 2031 |
Drugs and Companies using MARALIXIBAT CHLORIDE ingredient
NCE-1 date: 29 September, 2025
Market Authorisation Date: 10 April, 2025
Dosage: TABLET; SOLUTION
More Information on Dosage
LIVMARLI family patents
